DK1891962T3 - Glutathion-baseret afgivelsessystem - Google Patents

Glutathion-baseret afgivelsessystem

Info

Publication number
DK1891962T3
DK1891962T3 DK05292820.7T DK05292820T DK1891962T3 DK 1891962 T3 DK1891962 T3 DK 1891962T3 DK 05292820 T DK05292820 T DK 05292820T DK 1891962 T3 DK1891962 T3 DK 1891962T3
Authority
DK
Denmark
Prior art keywords
glutathion
delivery system
based delivery
delivery
Prior art date
Application number
DK05292820.7T
Other languages
English (en)
Inventor
Ae-June Wang
Chi-Heng Jian
Shyh-Dar Li
Yi-Fong Lin
Shih-Jr Liu
Original Assignee
Ind Tech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ind Tech Res Inst filed Critical Ind Tech Res Inst
Application granted granted Critical
Publication of DK1891962T3 publication Critical patent/DK1891962T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK05292820.7T 2005-12-19 2005-12-29 Glutathion-baseret afgivelsessystem DK1891962T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/303,934 US7446096B2 (en) 2005-12-19 2005-12-19 Glutathione based delivery system

Publications (1)

Publication Number Publication Date
DK1891962T3 true DK1891962T3 (da) 2014-10-13

Family

ID=36217526

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05292820.7T DK1891962T3 (da) 2005-12-19 2005-12-29 Glutathion-baseret afgivelsessystem

Country Status (11)

Country Link
US (4) US7446096B2 (da)
EP (2) EP1891962B1 (da)
JP (2) JP4773200B2 (da)
CN (2) CN101385859B (da)
CY (1) CY1115542T1 (da)
DK (1) DK1891962T3 (da)
ES (1) ES2516665T3 (da)
PL (1) PL1891962T3 (da)
PT (1) PT1891962E (da)
SI (1) SI1891962T1 (da)
TW (1) TWI365754B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US20040057983A1 (en) 2002-09-25 2004-03-25 David Schmidt Biomolecular wearable apparatus
DK1720551T3 (da) * 2004-03-03 2011-05-16 Vital Health Sciences Pty Ltd Alkaloidformuleringer
CA2575587C (en) * 2004-08-03 2014-06-17 Vital Health Sciences Pty Ltd Carrier for enteral administration
US20090239827A1 (en) * 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
NZ565049A (en) 2005-06-17 2012-02-24 Vital Health Sciences Pty Ltd A carrier comprising one or more DI and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US7446096B2 (en) * 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system
US8067380B2 (en) * 2005-12-19 2011-11-29 Industrial Technology Research Institute Glutathione-based delivery system
DK2308514T3 (da) * 2007-03-23 2013-09-02 To Bbb Holding B V Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren
FR2926725B1 (fr) * 2008-01-25 2010-09-03 Biochimie Appliquee Soc Compositions cosmetiques et/ou dermatologiques cicatrisantes
US8602961B2 (en) * 2008-05-15 2013-12-10 Lifewave Products Llc Apparatus and method of stimulating elevation of glutathione levels in a subject
KR101727333B1 (ko) * 2008-11-26 2017-04-14 추가이 세이야쿠 가부시키가이샤 베시클 제제
WO2010061881A1 (ja) 2008-11-26 2010-06-03 中外製薬株式会社 Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸
CA2752373C (en) * 2009-02-20 2017-10-10 To-Bbb Holding B.V. Glutathione-based drug delivery system
ES2999020T3 (en) 2010-02-05 2025-02-24 Phosphagenics Ltd Carrier comprising non-neutralised tocopheryl phosphate
EP2552486B1 (en) 2010-03-30 2020-08-12 Phosphagenics Limited Transdermal delivery patch
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
GB201302427D0 (en) * 2013-02-12 2013-03-27 Midatech Ltd Nanoparticle delivery compositions
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
US10307370B2 (en) 2013-10-08 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US10765755B1 (en) * 2013-11-20 2020-09-08 University Of South Florida Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies
DK3125875T3 (da) 2014-04-04 2023-07-24 Ai Therapeutics Inc Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
WO2015154897A1 (en) * 2014-04-08 2015-10-15 Wolfgang Stremmel Means and methods for treating disorders of copper metabolism
EP3131944B1 (en) * 2014-04-17 2018-12-05 The Corporation OF Mercer University Vitamin e-based nanocarriers for drug delivery and methods of making and using the same
KR20170095807A (ko) 2014-10-07 2017-08-23 램 테라퓨틱스, 인코포레이티드 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제
US10758520B1 (en) 2015-05-20 2020-09-01 University Of South Florida Glutathione-coated nanoparticles for delivery of MKT-077 across the blood-brain barrier
CN114712308A (zh) 2015-12-09 2022-07-08 磷肌酸有限公司 药物制剂
EP3558903B1 (en) 2016-12-21 2024-07-03 Avecho Biotechnology Limited Process for phosphorylating a complex alcohol
US10226442B2 (en) * 2017-07-10 2019-03-12 Syneurx International (Taiwan) Corp. Lithium salts of N-substituted glycine compounds and uses thereof
US10842755B2 (en) 2018-03-23 2020-11-24 University Of South Carolina Nanoparticles for brain targeted drug delivery
US20200048305A1 (en) * 2018-08-10 2020-02-13 South Dakota Board Of Regents Glutathione-cholesterol derivatives as brain targeting agents
WO2020242217A1 (ko) * 2019-05-28 2020-12-03 울산과학기술원 글루타치온-ｓ-전이효소 및 표적 세포 또는 표적 단백질 결합능을 갖는 단백질을 포함하는 리포좀 및 이의 용도
EP3954393A1 (en) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Combination therapies for delivery across the blood brain barrier
TW202228792A (zh) 2020-10-09 2022-08-01 殷漢生技股份有限公司 吸入用奈米載體製劑
CN118987236B (zh) * 2024-08-12 2025-07-22 中山大学附属第一医院 基于谷胱甘肽响应微环境活性氧实现靶向药物递送的载体系统及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60142915A (ja) 1983-12-28 1985-07-29 Lion Corp 口腔用組成物
JPS632922A (ja) 1986-06-20 1988-01-07 Yamanouchi Pharmaceut Co Ltd ドラツグキヤリア
JPH0714865B2 (ja) * 1986-10-28 1995-02-22 武田薬品工業株式会社 リポソ−ム製剤およびその製造法
FR2627385B3 (fr) 1988-02-23 1991-08-23 Serobiologiques Lab Sa Composition notamment utile comme matiere de base pour la preparation de compositions pharmaceutiques, notamment dermatologiques et/ou cosmetiques
US5695751A (en) 1993-04-08 1997-12-09 Cornell Research Foundation, Inc. Enhancing delivery of large neutral amino acid drugs
JPH0834779A (ja) * 1994-05-20 1996-02-06 Senju Pharmaceut Co Ltd トコフェロール誘導体
US6653331B2 (en) 1996-07-03 2003-11-25 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
JP2001523221A (ja) * 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
EP0932390A1 (en) * 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6228347B1 (en) 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
TW576838B (en) * 1998-04-16 2004-02-21 Teijin Ltd Glutathione derivatives and application form thereof
JP2004323486A (ja) * 2003-04-30 2004-11-18 National Institute Of Advanced Industrial & Technology 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬
CN100515390C (zh) * 2005-04-14 2009-07-22 蔡海德 垂体前叶肾上腺皮质提取物纳米脂质体组合药物及其制备方法和用途
US8067380B2 (en) * 2005-12-19 2011-11-29 Industrial Technology Research Institute Glutathione-based delivery system
US7446096B2 (en) * 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system

Also Published As

Publication number Publication date
CN101385859B (zh) 2011-12-07
CN1985804B (zh) 2014-05-14
EP2837384A1 (en) 2015-02-18
JP2007169252A (ja) 2007-07-05
US20080095836A1 (en) 2008-04-24
SI1891962T1 (sl) 2014-12-31
CN1985804A (zh) 2007-06-27
US20100166849A1 (en) 2010-07-01
US7700564B2 (en) 2010-04-20
TWI365754B (en) 2012-06-11
JP4773200B2 (ja) 2011-09-14
ES2516665T3 (es) 2014-10-31
JP5394944B2 (ja) 2014-01-22
CN101385859A (zh) 2009-03-18
CY1115542T1 (el) 2017-01-04
PT1891962E (pt) 2014-11-11
JP2010150264A (ja) 2010-07-08
US20090060991A1 (en) 2009-03-05
EP1891962B1 (en) 2014-08-13
US7446096B2 (en) 2008-11-04
US7704956B2 (en) 2010-04-27
PL1891962T3 (pl) 2015-01-30
EP1891962A1 (en) 2008-02-27
US8569239B2 (en) 2013-10-29
US20070141133A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
DK1891962T3 (da) Glutathion-baseret afgivelsessystem
DK1889198T3 (da) Farma-informatiksystem
DK1928521T3 (da) Trombektomikateterindsættelsessystem
FI20060131A0 (fi) Yhteysjärjestelmä
FI20050128L (fi) Hissijärjestelmä
DE602006003400D1 (de) Embolievorrichtungs-Abgabesystem
FI20050130A0 (fi) Hissijärjestelmä
FI20050504A0 (fi) Hissijärjestelmä
FI20050127A0 (fi) Hissijärjestelmä
DE602006015148D1 (de) Embolievorrichtung Abgabesystem
FI20050361L (fi) Hissijärjestelmä
DE502006007103D1 (de) Anschluss-system
DK1957073T3 (da) Lægemiddel
EP1964232A4 (en) HVDC SYSTEM
DE602007009224D1 (de) R-cellular-systemen
NL1030571A1 (nl) Geurafgiftesysteem.
NL1030597A1 (nl) Geurafgiftesysteem.
DE602006018435D1 (de) Surround-System
EP1951798A4 (en) BROMOBENZYLE FIRE RETARDANT SYSTEMS
ATE454037T1 (de) Haltesystem
DK1769359T3 (da) Publikationsdata-verifikationssystem
LU91233B1 (de) Laderaumsystem
FI6455U1 (fi) Virtuaali-ikkunajärjestelmä
SK4298U (sk) Doručenka
SK4297U (sk) Doručenka